<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35636">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02642640</url>
  </required_header>
  <id_info>
    <org_study_id>R01DK102696</org_study_id>
    <nct_id>NCT02642640</nct_id>
  </id_info>
  <brief_title>Interaction of Melatonin and MTNR1B Genotype on Glucose Control</brief_title>
  <official_title>Interaction of Melatonin and MTNR1B Genotype on Glucose Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to test the impact of melatonin and MTNR1B variation on regulation glucose
      regulation in a highly controlled in-laboratory setting and ex vivo in pancreatic islets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators' recent GWAS discovery of MTNR1B as a novel type 2 diabetes gene has
      sparked great interest into the role of melatonin in glycemic control, for which the
      mechanism is largely unknown. This research will determine the effect of melatonin and
      MTNR1B on glycemic control under highly-controlled, in-laboratory protocols while
      manipulating circulating melatonin concentrations (both up and down) and assessing glycemic
      control by frequently-sampled intravenous glucose tolerance tests, as well as in ex vivo
      human pancreatic islets. This research will provide mechanistic insights into the metabolic
      effects of melatonin and the MTNR1B risk variant and may help in evidence-based approaches
      and personalized recommendations to improve glycemic control in night shift workers and
      late-night eaters.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in disposition index</measure>
    <time_frame>Day 2, 3, 4 and/or 5 of the in-laboratory protocol</time_frame>
    <description>Disposition index will be determined by frequently sampled intravenous glucose tolerance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in first-phase insulin release</measure>
    <time_frame>Day 2, 3, 4 and/or 5 of the in-laboratory protocol</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in insulin sensitivity</measure>
    <time_frame>Day 2, 3, 4 and/or 5 of the in-laboratory protocol</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in glucose tolerance</measure>
    <time_frame>Day 2, 3, 4 and/or 5 of the in-laboratory protocol</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>change in plasma melatonin</measure>
    <time_frame>Day 2, 3, 4 and/or 5 of the in-laboratory protocol</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change in endocrine markers involved in glucose control, such as cortisol</measure>
    <time_frame>Day 2, 3, 4 and/or 5 of the in-laboratory protocol</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change in measures of autonomic function such as catecholamines</measure>
    <time_frame>Day 2, 3, 4 and/or 5 of the in-laboratory protocol</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change in measures of thermoregulation including core body temperature</measure>
    <time_frame>Day 2, 3, 4 and/or 5 of the in-laboratory protocol</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change in measures of sleep and/or wake by EEG, such as total sleep duration</measure>
    <time_frame>Day 2, 3, 4 and/or 5 of the in-laboratory protocol</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change in energy expenditure by indirect calorimetry</measure>
    <time_frame>Day 2, 3, 4 and/or 5 of the in-laboratory protocol</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change in hunger and appetite ratings by visual analogue scale</measure>
    <time_frame>Day 2, 3, 4 and/or 5 of the in-laboratory protocol</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change in measures of sleep and cognitive performance such as by PVT</measure>
    <time_frame>Day 2, 3, 4 and/or 5 of the in-laboratory protocol</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change in blood pressure</measure>
    <time_frame>Day 2, 3, 4 and/or 5 of the in-laboratory protocol</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Glucose</condition>
  <condition>Circadian Rhythm</condition>
  <condition>Melatonin</condition>
  <condition>Genes</condition>
  <arm_group>
    <arm_group_label>melatonin-placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>subjects will receive melatonin first and placebo second</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo-melatonin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>subjects will receive placebo first and melatonin second</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>melatonin</intervention_name>
    <description>5 mg of melatonin per os.</description>
    <arm_group_label>melatonin-placebo</arm_group_label>
    <arm_group_label>placebo-melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>melatonin-placebo</arm_group_label>
    <arm_group_label>placebo-melatonin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index: 18.5 and 39.9 kg/m2

          -  Age: 18-60 years of age

          -  Caucasian

          -  Non-smoking

          -  With regular sleep-wake cycle

          -  Passed medical and psychological screening tests

        Exclusion Criteria:

          -  Acute, chronic or debilitating medical conditions

          -  History of neurological or psychiatric disorder

          -  History of sleep disorder or regular use of sleep-promoting medication

          -  Current prescription, herbal, or over-the-counter medication use

          -  Traveling across 2 or more time zones within past 3 months

          -  Worked night or rotating shift work within past 1 year

          -  Drug or alcohol dependency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank AJL Scheer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frank AJL Scheer, PhD</last_name>
    <phone>617-732-7014</phone>
    <email>fscheer@bwh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jingyi Qian, PhD</last_name>
    <phone>617-525-7423</phone>
    <email>jqian5@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Byrne</last_name>
      <phone>617-525-8655</phone>
      <email>sbyrne4@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Jingyi Qian, PhD</last_name>
      <phone>617-525-7423</phone>
      <email>jqian5@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>Frank AJL Scheer, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 8, 2016</lastchanged_date>
  <firstreceived_date>December 21, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Frank AJL Scheer, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
